Phase II Trial for Bertilimumab for Ulcerative Colitis Launched

Phase II Trial for Bertilimumab for Ulcerative Colitis Launched
Massachusetts-based Immune Pharmaceuticals Inc., a company that specializes in creating antibody therapeutics for chronic inflammatory conditions, recently announced the start of participant screening for its Phase II clinical trial of one of their lead therapeutic products for ulcerative colitis, called Bertilimumab. Ulcerative colitis is a form of inflammatory bowel disease confined to the colon. It typically manifests as painful,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *